Helena Vivancos Bargalló
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Helena Vivancos Bargalló has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Natalia Tejedor Aguilar
Medical Physics Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2 shared publications - Adam Yeo
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; RMIT University, School of Applied Sciences, Melbourne, Australia
1 shared publication - Ana Peiró
Department of Orthopedic and Traumatology Surgery, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
1 shared publication - Ana Sebio
Medical Oncology Department, Santa Creu i Sant Pau University Hospital, 08025 Barcelona, Spain
1 shared publication - Andrea Molineu
Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Antonio Vila Capel
Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Calle Sant Quintí 89, 08041 Barcelona, Spain
1 shared publication
Latest Publications
- 21 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111829
Harmonizing spatially fractionated radiation therapy: consensus and roadmap from an ESTRO workshop
- 21 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111829
Harmonizing spatially fractionated radiation therapy: consensus and roadmap from an ESTRO workshop
- Top Cited PapersOpen Access
Role of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas
Background: The clinical outcome of inoperable sarcoma patients treated with LATTICE (LRT) is limited and therefore the objective of our study was to report treatment response, overall survival (OS), local-recurrence free survival (LRFS) and toxicity. Methods: This retrospective observational study includes 15 histologically proven inoperable non-extremity sarcoma patients with no treatment options or no response to systemic therapy, treated at our institution between 2020 and 2024. The patients were treated with a combination of LRT and normo- or hypo-fractionated external beam radiotherapy. Treatment response was evaluated by RECIST1.1 criteria, toxicity by CTCAE 5.0 and OS and LRFS by Kaplan–Meier curves. Results: The median follow-up (F-UP) since the beginning of the treatment was 10 months (range 4–32). Nine patients were male and six female. Their mean age was 60 years. The median gross tumor volume (GTV) was 1058 cm3 (range 142–6103 cm3). The median number of spheres was 9 (4–30). All patients with symptoms reported symptoms’ relief. Based on RECIST1.1 criteria, 10 patients (67%) had stable local disease at 1–2 months F-UP on computed tomography (CT). Surgical resection was feasible in five patients. Three of them are alive without disease and two died due to metastatic progression. From 10 (67%) non operated patients, 5 patients died (50%) due to disease. The remaining five patients (50%) are alive, three with stable disease at 21, 22, and 32 months of F-UP and two with disease progression who are currently receiving palliative chemotherapy treatment. Reported G2 toxicity was as follows: gastrointestinal (2), asthenia (1). Two patients had G3 toxicity: esophagitis (1) and inguinal dermatitis (1). No acute or chronic G4–G5 toxicity was observed. Conclusions: LRT is a feasible and well-tolerated radiation technique for inoperable bulky soft-tissue sarcomas. Further studies are needed to establish protocols to determine which patients could benefit from palliative or preoperative treatment.
Top Cited PapersOpen AccessRole of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas
Background: The clinical outcome of inoperable sarcoma patients treated with LATTICE (LRT) is limited and therefore the objective of our study was to report treatment response, overall survival (OS), local-recurrence free survival (LRFS) and toxicity. Methods: This retrospective observational study includes 15 histologically proven inoperable non-extremity sarcoma patients with no treatment options or no response to systemic therapy, treated at our institution between 2020 and 2024. The patients were treated with a combination of LRT and normo- or hypo-fractionated external beam radiotherapy. Treatment response was evaluated by RECIST1.1 criteria, toxicity by CTCAE 5.0 and OS and LRFS by Kaplan–Meier curves. Results: The median follow-up (F-UP) since the beginning of the treatment was 10 months (range 4–32). Nine patients were male and six female. Their mean age was 60 years. The median gross tumor volume (GTV) was 1058 cm3 (range 142–6103 cm3). The median number of spheres was 9 (4–30). All patients with symptoms reported symptoms’ relief. Based on RECIST1.1 criteria, 10 patients (67%) had stable local disease at 1–2 months F-UP on computed tomography (CT). Surgical resection was feasible in five patients. Three of them are alive without disease and two died due to metastatic progression. From 10 (67%) non operated patients, 5 patients died (50%) due to disease. The remaining five patients (50%) are alive, three with stable disease at 21, 22, and 32 months of F-UP and two with disease progression who are currently receiving palliative chemotherapy treatment. Reported G2 toxicity was as follows: gastrointestinal (2), asthenia (1). Two patients had G3 toxicity: esophagitis (1) and inguinal dermatitis (1). No acute or chronic G4–G5 toxicity was observed. Conclusions: LRT is a feasible and well-tolerated radiation technique for inoperable bulky soft-tissue sarcomas. Further studies are needed to establish protocols to determine which patients could benefit from palliative or preoperative treatment.
- 16 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1546-1550
Classification of laterality and mastectomy/lumpectomy for breast cancer patients for improved performance of deep learning auto segmentation
- 16 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1546-1550
Classification of laterality and mastectomy/lumpectomy for breast cancer patients for improved performance of deep learning auto segmentation